Hera Biotech Acquires Endometriosis Dx Assets From Scailyte, Raises $15M in Series A Round

The companies have demonstrated significant changes in the transcriptomes of endometrium samples obtained from endometriosis patients compared to control patient samples.

Full story: http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6595ce61e3504e99aa37898a507ba206&url=https%3a%2f%2fwww.360dx.com%2fbusiness-news%2fhera-biotech-acquires-endometriosis-dx-assets-scailyte-raises-15m-series-round&c=8176253442805861030&mkt=en-us